Ocuphire Announces the US Commercial Launch of RYZUMVl (Phentolamine Ophthalmic Solution 0.75%) by Its Partner Viatris
Ocuphire Announces the US Commercial Launch of RYZUMVl (Phentolamine Ophthalmic Solution 0.75%) by Its Partner Viatris
Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. commercial launch of RYZUMVI (phentolamine ophthalmic solution) by its partner Viatris Inc. (NASDAQ:VTRS).
Ocuphire has a global license agreement with Viatris to co-develop and commercialize Phentolamine Ophthalmic Solution 0.75%. Under the terms of this agreement, Ocuphire is eligible to receive regulatory and commercial milestones as well as royalties.
Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. commercial launch of RYZUMVI (phentolamine ophthalmic solution) by its partner Viatris Inc. (NASDAQ:VTRS).
Ocuphire Pharma, Inc.（納斯達克股票代碼：OCUP）是一家臨床階段的生物製藥公司，專注於開發治療視網膜和屈光眼疾患者未得到滿足的需求的新療法。該公司今天宣佈，其合作伙伴維亞特里斯公司（納斯達克股票代碼：VTRS）將在美國商業推出RYZUMVI（酚妥拉明眼科解決方案）。
Ocuphire has a global license agreement with Viatris to co-develop and commercialize Phentolamine Ophthalmic Solution 0.75%. Under the terms of this agreement, Ocuphire is eligible to receive regulatory and commercial milestones as well as royalties.
Ocuphire與Viatris簽訂了全球許可協議，共同開發和商業化0.75％的酚妥拉明眼科溶液。根據本協議的條款，Ocuphire有資格獲得監管和商業里程碑以及特許權使用費。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧